Evaluation Of Comorbidities And Damage In Canadian Patients With Systemic Lupus Erythematosus

BackgroundSystemic Lupus Erythematosus (SLE) is a chronic autoimmune disease with a wide array of clinical manifestations, treated with corticosteroids and long term immunosuppressants to reduce the disease activity and damage. Our objectives were to examine a Canadian cohort of SLE patients in comparison to the general Canadian population to examine potential risk factors for comorbidities and disease damage in SLE patients. We hypothesize that SLE patients accumulate more damage and comorbidities with greater disease activity and corticosteroid exposure over time compared to the general population.MethodsWe explored the Canadian Network for Improved Outcomes in SLE (CaNIOS) registry, a multi-centred cohort of Canadian SLE patients, to identify prevalence of damage using the SLICC SLE Damage Index (SDI) and comorbidity using the Charlson Comorbidity Index (CCI). We also performed an age-matched data analysis to compare the comorbidities prevalence between the CaNIOS registry and the general Canadian population (Canadian Community Health Survey). Exploratory analysis was done using descriptive statistics. Univariable analysis was performed to identify potential predictors of comorbidities and damage in the CaNIOS SLE population at baseline. Variables that were significant at the univariable level were included in Generalized Linear Model (GLM).Results603 SLE patients from the CaNIOS registry were included, mean age 50.9 years (SD=14.6), average disease duration 14.2 years (SD=11.9), 91% being female. Mean SLE disease activity score (SLEDAI) was 3.1 (SD 3.5) and mean ACR classification criteria 5.3 (1.5). Mean CCI was 1.33 (SD=0.69), and mean SDI was 1.34 (SD=2.04). The most common comorbidities in CaNIOS patients were cerebrovascular disease (6.5%), followed by solid tumours (5.8%). Compared to their age-matched general population counterparts, SLE patients had higher rates of cancer (7.8% vs 2%) and cerebrovascular disease (6.5% vs 1.8%) (p<0.0001). Multivariable GLM showed age to be a significant predictor for increased comorbidities (p<0.05). Baseline risk factors associated with increased damage (SDI) were age, longer disease duration, higher ACR scores, current smoking and prednisone use within the last year (p<0.05). Female gender (p<0.0160), a recent onset of disease (<12 months) (p<0.0001) and intravenous steroid use (p<0.0286) were found to be associated with less disease damage.ConclusionsCanadian lupus patients have a greater burden of certain comorbidities compared to the general population. Identifying the risk factors associated with comorbidities and greater disease damage is a very important step in treating those patients.AcknowledgementThis study is on behalf of CANIOS (Canadian Network of Improved Outcomes in SLE) authors: Jennifer Reynolds, Antonio Avina-Zubieta, Ann Clarke, Carol Hitchon, Annaliese Tisseverasinghe, Paul Fortin, Catherine Ivory, Derek Haaland, Kim Legault, Mark Matsos, Janet Pope